OncoSil Medical Ltd
OncoSil Medical Ltd
Your view on OSL.AX
Overview
What the company does, where it operates, and who runs it.
About OncoSil Medical Ltd
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Nigel Lange
- Headquarters
- 7 Eden Park Drive, Macquarie Park, NSW, AU
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Nigel Lange
- Headquarters
- 7 Eden Park Drive, Macquarie Park, NSW, AU
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for OncoSil Medical Ltd, and the rating behind it. OSL.AX last traded at AUD 1.25; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for OncoSil Medical Ltd. Starting points for OncoSil Medical Ltd: EPS -AUD 0.95, beta 1.17 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for OncoSil Medical Ltd. OncoSil Medical Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for OncoSil Medical Ltd. Trailing twelve-month EPS for OncoSil Medical Ltd stands at -AUD 0.95. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for OncoSil Medical Ltd. OncoSil Medical Ltd has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
OncoSil Medical Ltd valued side by side against its closest peers. OncoSil Medical Ltd is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold OncoSil Medical Ltd, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by OncoSil Medical Ltd executives and directors. Shares of OncoSil Medical Ltd have traded between AUD 0.37 and AUD 2.09 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming OncoSil Medical Ltd. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming OncoSil Medical Ltd. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for OncoSil Medical Ltd. Coverage tracks OncoSil Medical Ltd within Medical - Devices (Healthcare). Press releases and market coverage, newest first.